$189.77 1.1%
ABBV Stock Price vs. AI Score
Data gathered: July 9

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - AbbVie (ABBV)

Analysis generated April 13, 2025. Powered by Chat GPT.

AbbVie, a global biopharmaceutical company, was spun off from Abbott Laboratories in 2013. The company specializes in developing and marketing advanced therapies that address some of the greatest health challenges today. AbbVie's primary focus areas include immunology, oncology, virology, and neuroscience. With a diversified portfolio of drugs, including blockbuster products like Humira, AbbVie has positioned itself as a formidable entity in the pharmaceutical industry.

Read full AI stock Analysis

Stock Alerts - AbbVie (ABBV)

company logo AbbVie | July 8
News Alert: AbbVie to Acquire Capstan Therapeutics for $2.1B, Boosting Autoimmune Pipeline
company logo AbbVie | July 1
News Alert: AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
company logo AbbVie | June 12
Josh Gottheimer (member of U.S. congress) is buying shares
company logo AbbVie | June 10
Rob Bresnahan (member of U.S. congress) is buying shares

Download our app to get future alerts delivered in real-time.

About AbbVie

AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.


AbbVie
Price $189.77
Target Price Sign up
Volume 5,340,000
Market Cap $334B
Year Range $161.92 - $214.67
Dividend Yield 3.53%
PE Ratio 79.84
Analyst Rating 71% buy
Earnings Date July 31 '25
Industry Drug Manufacturers

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2513.3B4B11.2B1.29B3.73B2.460
Q4 '2415.1B10.5B10.7B-22M566M2.160
Q3 '2414.5B4.21B10.2B1.56B4.93B3.000
Q2 '2414.5B2.18B12.3B1.37B7.13B2.650
Q1 '2412.3B4.08B8.23B1.37B5.56B2.310

Insider Transactions View All

Stewart Jeffrey Ryan filed to sell 86,366 shares at $209.5.
April 2 '25
Stewart Jeffrey Ryan filed to sell 53,234 shares at $210.5.
April 2 '25
Reents Scott T filed to sell 11,577 shares at $212.3.
March 18 '25
RICHMOND TIMOTHY J. filed to sell 6,130 shares at $211.3.
March 4 '25
GONZALEZ RICHARD A filed to sell 388,929 shares at $210.5.
March 4 '25

What is the Market Cap of AbbVie?

The Market Cap of AbbVie is $334B.

What is AbbVie's PE Ratio?

As of today, AbbVie's PE (Price to Earnings) ratio is 79.84.

When does AbbVie report earnings?

AbbVie will report its next earnings on July 31 '25.

What is the current stock price of AbbVie?

Currently, the price of one share of AbbVie stock is $189.77.

How can I analyze the ABBV stock price chart for investment decisions?

The ABBV stock price chart above provides a comprehensive visual representation of AbbVie's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling AbbVie shares. Our platform offers an up-to-date ABBV stock price chart, along with technical data analysis and alternative data insights.

Does ABBV offer dividends to its shareholders?

Yes, AbbVie (ABBV) offers dividends to its shareholders, with a dividend yield of 3.53%. This dividend yield represents AbbVie's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering AbbVie in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.

What are some of the similar stocks of AbbVie?

Some of the similar stocks of AbbVie are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and TherapeuticsMD.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.

Chat with AltIndex AI

👋 Welcome to AltIndex AI Chat!

Ask about:
  • Top Stocks
  • AI score insights
  • Trending investment opportunities
  • How to use AltIndex
You need to log in to use AltIndex AI Chat.
Disclaimer: AI outputs may be incorrect. This is for informational purposes only and not a substitute for professional financial advice.